Taurine identified as a key skeletal cancer regulator

The new scientific research identified Taurin, which is naturally produced in the body and consumed by some foods, as a key sofa cancer regulator, such as leukemia, in accordance with the article published in the magazine

Post -clinical studies show that scientists are one step closer to finding new ways to aim at leukemia, which is one of the most aggressive blood cancers. Wilmot Cancer Institute researchers from the University of Rochester were able to block the growth of leukemia in mouse models and leukemia samples using genetic tools to prevent cancer cells.

The research team led by Dr. Jevish Bajej, discovered that taurine is produced by a subset of normal cells in a bone marrow microenvil, tissue inside the bones, in which myelomic crayfish begin and develop. Backyard cells are not able to make taurine alone, so they rely on the Taurine transporter (coded by the SLC6A6 gene) to grab Taurine from the bone marrow environment and deliver it to cancer cells.

The discovery occurred because scientists mapped what is happening in the bone marrow and its ecosystem-class among Wilmot scientists who developed science around the micro-environment in order to improve blood cancer treatment.

We are very excited about these studies because they show that aiming at the closure leukemia cells can be a new way to treat these aggressive diseases. “

Dr. Jevisha Bajej, professor assistant at the Faculty of Biomedical Genetics and a member of the Wilmot’s Cancer Micromeririronment research program

Researchers also found that when leukemia cells drink taurine, it promotes glycolize (glucose distribution to produce energy) to supply cancer growth. Earlier, the authors said that it is not known that taurine can play the role of promoting cancer.

Leukemia has several subtypes, and survival indicators are different. In this study, it was found that the expression of the Taurine transporter is necessary for the growth of many subtypes, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and hyalodisplastic syndromes (MDS), which come from blood stem cells in the bone marrow. Future research will examine the signals from the microenvil that promote the passage of MDS, precursor of leukemia, acute leukemia.

What is taurine?

Irregular amino acid occurs not only naturally in the bone marrow, but also in the brain, heart and muscles. Foods such as meat, fish and eggs contain taurine. It is also a key component of some energy drinks and protein powders, and an anecdotally was used by cancer patients.

Bajej said that this is a hot research area that is still developing and where context is meaning. For example, last year, the research article in the journal showed the results of Taurine’s study on stomach cancers and found that supplements can benefit some patients by increasing the immune system.

Jane Liesveld, MD, oncologist Wilmot, who treats people with leukemia and work co -author, noticed that scientists still have a lot to know how leukemia cells are reprogrammed and take energy to develop and resistance to treatment.

“The work of Dr. Bajaja shows that local levels of taurine in the bone marrow can increase the growth of leukemia, suggesting caution in the use of high dose taurine supplementation,” said Liesveld.

“Metabolic reprogramming is the hallmark of cancer, and we are at the beginning of understanding the metabolic effect on leukemia,” she added. “Earlier emphasis was placed on genetic changes, but it was focused on understanding how leukemia cells are able to kidnap various metabolic routes for their own experience.”

To sum up, the Wilmot team states in their article: “Because taurine is a common component of energy drinks and is often supplied as a supplement to relieve the side effects of chemotherapy, our work suggests that it can be interesting to carefully consider the benefits of additional taurine in patients with leukemia.”

Bajej said that future research should examine taurine levels in people with leukemia. But most importantly: “Our current data suggest that it would be helpful to develop stable and effective ways of blocking taurine before entering leukemia cells,” she said.

The study included a wide cooperation between the Baaj laboratory, the Genomics Research Center led by dr John Ashton, MBA, members of the Wilmot Cancer and Genetics microenvil program, Epigenetics and metabolism program (GEM). Data from a former member of the Wilmot Department Dr. Craig Jordan also contributed to the report. Co -chairing the authors in the newspaper who carried out a significant part of the work in the Bajej laboratory are: Dr. Sonali Sharma, post -coating collaborator; Benjamin Rodems, MS, senior technician; Cameron Baker, MS, senior bioinformatics analyst; And Dr. Christina Kaszuba. The main founders were the National Cancer Institute and the National Institute of Diabetes and Permestive and Nerph diseases, both of which are part of the National Institutes of Health. Also American Society of Hematology, The Leukemia Research Foundation and Leukemia & Lymphom Society.